Skip to main content

Table 1 Clinical and morphological characteristics of patients with or without chemo-resistance

From: Clinical analysis of chemo-resistance risk factors in endometriosis associated ovarian cancer

Variable

Category

Number(%)

Chemo-sensitive(%)

Chemoresistance(%)

P

  

304

252(82.9%)

52(17.1%)

 

Age

< 48

129(42.43)

114(45.24)

15(28.85)

0.0294*

≥48

175(57.57)

138(54.76)

37(71.15)

 

Menopausal status

Pre

161(52.96)

139(55.16)

22(42.31)

0.0909

Post

143(47.04)

113(44.84)

30(57.69)

 

Gravidity

< 1

35(11.51)

31(12.3)

4(7.69)

0.3431

> = 1

269(88.49)

221(87.7)

48(92.31)

 

Parity

< 1

51(16.78)

46(18.25)

5(9.62)

0.1290

> = 1

253(83.22)

206(81.75)

47(90.38)

 

Abdominal pain

No

210(69.08)

174(69.05)

36(69.23)

0.9016

Yes

93(30.59)

77(30.56)

16(30.77)

 

Bloating

No

243(79.93)

208(82.54)

35(67.31)

0.0125*

Yes

61(20.07)

44(17.46)

17(32.69)

 

Palpable mass

No

223(73.36)

182(72.22)

41(78.85)

0.3253

Yes

81(26.64)

70(27.78)

11(21.15)

 

Incidental finding

No

256(84.21)

208(82.54)

48(92.31)

0.0786

Yes

48(15.79)

44(17.46)

4(7.69)

 

Irregular menstruation

No

275(90.46)

226(89.68)

49(94.23)

0.3094

Yes

29(9.54)

26(10.32)

3(5.77)

 

Postmenopausal bleeding

No

285(93.75)

235(93.25)

50(96.15)

0.4316

Yes

19(6.25)

17(6.75)

2(3.85)

 

Emaciation

No

294(96.71)

248(98.41)

46(88.46)

0.0002*

Yes

10(3.29)

4(1.59)

6(11.54)

 

Abnormal vaginal discharge

No

302(99.34)

250(99.21)

52(100)

0.5192

Yes

2(0.66)

2(0.79)

0(0)

 

Ca125 in normal range(< 35 U/L)

No

249(81.91)

199(78.97)

50(96.15)

0.0034*

Yes

55(18.09)

53(21.03)

2(3.85)

 

CA125group

< 90

112(36.84)

104(41.27)

8(15.38)

0.0004*

≥90

192(63.16)

148(58.73)

44(84.62)

 

Early or late Stage

FIGO I + II

185(60.86)

175(69.44)

10(19.23)

<.0001*

FIGO III + IV

119(39.14)

77(30.56)

42(80.77)

 

FIGO stagea

I

141(46.38)

136(53.97)

5(9.62)

<.0001*

II

44(14.47)

39(15.48)

5(9.62)

 

III

104(34.21)

69(27.38)

35(67.31)

 

IV

15(4.93)

8(3.17)

7(13.46)

 

Tumor size group

< 7

80(26.32)

66(26.19)

14(26.92)

0.9130

≥7

224(73.68)

186(73.81)

38(73.08)

 

Pathology Grade

G1

45(24.19)

44(28.03)

1(3.45)

0.0128*

G2

59(31.72)

49(31.21)

10(34.48)

 

G3

82(44.09)

64(40.76)

18(62.07)

 

Pathology type

Endometrioid

186(61.18)

157(62.30)

29(55.77)

0.435

Clear cell

118(38.82)

95(37.70)

23(44.23)

 

Endometriosis

No

235(77.30)

188(74.6)

47(90.38)

0.0134*

Yes

69(22.70)

64(25.4)

5(9.62)

 

Side of tumor

Unilateral

212(69.74)

183(72.62)

29(55.77)

0.0160*

Bilateral

92(30.26)

69(27.38)

23(44.23)

 

LN metastasis

No

213(70.07)

195(77.38)

18(34.62)

<.0001*

Yes

40(13.16)

24(9.52)

16(30.77)

 

unclear

51(16.78)

33(13.1)

18(34.62)

 

LN dissection

No

51(16.78)

33(13.1)

18(34.62)

0.0002*

Yes

253(83.22)

219(86.9)

34(65.38)

 

Residual disease

No

231(75.99)

207(82.14)

24(46.15)

<.0001*

Yes

73(24.01)

45(17.86)

28(53.85)

 

TH

No

297(97.7)

246(97.62)

51(98.08)

0.8411

Yes

7(2.3)

6(2.38)

1(1.92)

 

Tubal ligation

No

290(95.39)

243(96.43)

47(90.38)

0.0583

Yes

14(4.61)

9(3.57)

5(9.62)

 

Sterilization surgery

No

283(93.09)

237(94.05)

46(88.46)

0.1481

Yes

21(6.91)

15(5.95)

6(11.54)

 

Endometrial disorder

No

252(82.89)

208(82.54)

44(84.62)

0.7174

Yes

52(17.11)

44(17.46)

8(15.38)

 

Variable endometrial disorder

No

252(82.89)

207(82.14)

45(86.54)

0.7998

EP

27(8.88)

23(9.13)

4(7.69)

 

EIN

22(7.24)

19(7.54)

3(5.77)

 

EC

3(0.99)

3(1.19)

0(0)

 

Breast cancer

No

296(97.37)

248(98.41)

48(92.31)

0.0123*

Yes

8(2.63)

4(1.59)

4(7.69)

 

HT

No

250(82.24)

208(82.54)

42(80.77)

0.7610

Yes

54(17.76)

44(17.46)

10(19.23)

 

DM

No

286(94.08)

236(93.65)

50(96.15)

0.4862

Yes

18(5.92)

16(6.35)

2(3.85)

 
  1. aAccording to the classification system of FIGO staging (2013 version)
  2. Abbreviation: Ca125 cancer antigen 125, EM endometriosis, LN lymph node, TH total hysterectomy, EP endometrial polyps, EIN endometrial intraepithelial neoplasm, EC endometrial cancer, HT hypertension, DM diabetic mellitus
  3. *P < 0.05